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Summary
Objectives To describe the epidemiology of end stage renal disease
(ESRD).
Design Mixed-methods systematic review.
Setting The countries of the Gulf Cooperation Council (GCC) which
consist of Saudi Arabia, the United Arab Emirates, Kuwait, Qatar, Bahrain,
and Oman.
Participants Deﬁned to have ESRD or patients on regular dialysis fora
minimum dialysis period of at least three months. Since many outcomes
were reviewed, studies that estimated the incidence and prevalence of
ESRD as outcomes should not have deﬁned the study population as ESRD
population or patients on regular dialysis. Studies where the study
population mainly comprised children or pregnant woman were excluded.
Main outcome measures The trends of the incidence, prevalence,
and mortality rate of ESRD; also, causes of mortality, primary causes and
co-morbid conditions associated with ESRD.
Results 44 studies included in this review show that the incidence of
ESRD has increased while the prevalence and mortality rate of ESRD in the
GCC has not been reported sufﬁciently. The leading primary causes of
ESRD recorded in the countries of the GCC is diabetes with the most
prevalent co-morbid conditions being Hypertension and Hepatitis C Virus
infection; the most common cause of death was cardiovascular disease
and sepsis.
Conclusions This review highlights that the lack of national renal
registries data is a critical issue in the countries of the GCC. The available
data also do not provide an accurate and updated estimate for relevant
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1outcomes. Additionally, considering the increasing burden of chronic
kidney disease (CKD), these results stressed the needs and the importance
of preventative strategies for leading causes of ESRD. Furthermore, more
studies are needed to describe the epidemiology of ESRD and for
assessing the overall quality of renal care.
Introduction
End-stage renal disease (ESRD) is deﬁned as irre-
versible decline in kidney function, when renal
replacement therapy (RRT) is needed for survival.
There are two main types of RRT: dialysis and
kidney transplantation.
1 Kidney transplantation
is preferred for patients with ESRD since it offers
a longer life span, superior quality of life, and is
more cost effective than long-term dialysis.
2
ESRD has become a public health concern world-
wide, with recent reports showing that the total
number of ESRD patients has been growing dra-
matically.
3–8 The rising prevalence is due largely
to two main factors; the ageing of the population
and the global epidemic of diabetes.
3
The countries of the Gulf Cooperation Council
(GCC), which consist of Saudi Arabia, the
United Arab Emirates, Kuwait, Qatar, Bahrain,
and Oman, share a similar background of culture
and ethnicity, while their socio-demographic dis-
tributions and socioeconomic development are
also similar.
4 Although the countries of the GCC
have experienced noticeable advances in deliver-
ing healthcare, the burden of non-communicable
diseases is increasing rapidly.
5 Many reports
have shown evidence of increasing prevalence of
the most common causes of ESRD in the GCC:
the prevalence of obesity in these countries,
which is associated with multi-chronic diseases,
exceeds that in the developed countries because
of their rapid economic growth and associated
changes in lifestyle.
6–8 Furthermore, the Inter-
national Diabetes Federation reports that ﬁve of
the countries of the GCC ranked globally among
the top ten countries in the world for diabetes
prevalence.
9
The growing incidence of ESRD is increasing
the use of RRT, as well as generating greater mor-
bidity, and more hospitalizations. These in turn
increase healthcare expenditures, placing a heavy
ﬁnancial burden on healthcare providers and
general populations to meet the growing needs
of patients with ESRD.
10,11 However, ESRD has a
signiﬁcant effect on public health in the countries
of the GCC, as the policy of these countries pro-
vides free health services including RRT to the
population based on clinical need without any
restrictions in terms of age, gender, or social
status. Because the majority of RRT facilities are
provided by the governmental sector, any increase
in its use would be associated with a signiﬁcant
increase of healthcare expenditures.
ESRD also has a signiﬁcant effect on quality of
life and life expectancy.
12 Most patients receive
haemodialysis treatment for ESRD by being con-
nected three times per week to a dialysis
machine for several hours at a time. People with
ESRD are more likely than those without the
illness to develop cardiovascular disease, the most
common cause of death in those with ESRD.
13
Scarce data is available on the epidemiology of
ESRD in the countries of the GCC. In the absence
of national renal registries system in these
countries, data that do exist are unsatisfactory
and insufﬁcient: most data are either recorded by
referring centres rather than community hospitals
such as Saudi Centre for Organ Transplantation
(SCOT) data; or based on small studies.
However, analyses of the epidemiology of ESRD
itself in this region are also inconsistent. For
example, the prevalence of ESRD decreased
between 1986 and 2005, a period when risk
factors for the disease became more common;
this might be due to underreporting the cases of
ESRD
14,15 or might be inﬂuenced by mortality
and renal transplant rate. Other articles report
inconsistent results of primary causes of
ESRD.
11,16 These conﬂicting analyses of the epide-
miology of ESRD mean that synthesizing and
assessing the evidence available would be
valuable.
This review was conducted to synthesize the
results of all relevant studies to describe the epide-
miology of ESRD in the countries of the GCC
based on: incidence, prevalence, patient charac-
teristics (age, sex, RRT), primary causes,
co-morbidities associated with ESRD, mortality
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Muhammad Shahidrate and causes of death in the ESRD population.
This was done by indentifying and reviewing
the published epidemiological studies of ESRD
in the countries of the GCC.
Methods
Systematic review
A systematic review was conducted by searching
Medline and EMBASE databases, to identify all
relevant papers published from 1950 until May
2010; using the following keywords in the search-
ing strategy:
End stage, terminal, chronic, renal, kidney, Arab,
Middle East, Arabian Gulf, Saudi Arabia, Kuwait,
and United Arab Emirates, Oman, Qatar, and
Bahrain.
Additionally, the reference lists of all identiﬁed
papers were reviewed to identify other papers,
which were not identiﬁed in the database search.
All the titles and abstracts of references were
reviewed independently by two reviewers to
identify relevant papers. Then, the full texts of
the papers were reviewed to identify epidemiolo-
gical studies that fulﬁlled the following criteria:
any observational epidemiological study includ-
ing cohort studies, case control studies, cross-
sectional studies, and ecological studies; report-
ing ESRD incidence, prevalence, primary causes,
co-morbidities conditions, mortality rate/causes
were included in this review. In addition, all the
studies have been deﬁned by the study popu-
lation to have ESRD or involve patients on
regular dialysis for a minimum dialysis period
of at least three months in any of the countries
of the GCC. Since many outcomes were reviewed
in this systematic review, studies that estimated
the incidence and prevalence of ESRD as out-
comes should not have deﬁned the study popu-
lation as ESRD population or patients on
regular dialysis. Studies where the study popu-
lation mainly comprised children, or pregnant
woman, or patients on regular dialysis without
mentioning the dialysis period or a period less
than three months were excluded. In addition,
the studies that do not report any statistical infor-
mation about any relevant outcomes were
excluded.
Studies that met the inclusion criteria for the
review had data extracted. Data relating to study
design, setting, deﬁnition of outcomes measure,
inclusion and exclusion criteria of study popu-
lation, methodological quality using the Newcas-
tle Ottawa Scale (NOS)
17 and outcomes were
then independently extracted by two reviewers
using standardized data extraction form. In meth-
odological quality assessment NOS, the included
studies were classiﬁed after aggregating the score
as follows: scores of seven or higher were chosen
to indicate higher methodological quality, a score
less than seven indicates a lower methodological
quality.
Some outcomes such as primary causes and
co-morbidities were classiﬁed as follows: primary
causes of ESRD were classiﬁed as in the ICD9-
CM code, which was updated in 2008 because
there were no studies in this review used standar-
dized methods to classify the primary causes.
Co-morbidities associated with ESRD were classi-
ﬁed into three groups: chronic diseases, infectious
diseases, and other co-morbidities.
Data analysis
The extracted data for patients’ characteristics,
prevalence, incidence, and mortality rate of
ESRD were analyzed descriptively. The data
related to primary causes, co-morbidities, and
causes of death were entered to STATAversion 10
for statistical analysis. These data were then used
to conduct meta-analysis to summarize the preva-
lence of each outcome where possible. The degree
of heterogeneity was assessed between the studies
statistically using meta-analysis to obtain an
I-square value.
18 This review combined the
results from observational studies, therefore it
would be expected that the value of I-square
would be high due to sampling, methodological
and statistical variation of the studies. To account
for the anticipated heterogeneity, the random
effect method was used to combine the measure
of effect (DerSimonian and Laird model). Sub-
group analysis was performed when it was
needed to investigate the reasons for heterogen-
eity between the studies; it was used to assess
the differences between locations and time. Fur-
thermore, the measures of uncertainty (95% conﬁ-
dence intervals (CIs) were calculated where
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3meta-analysis was not appropriate to conduct for
any outcome especially for those that reported in
less than three studies.
Results
The search identiﬁed 226 articles published from
1950 to May 2010. After reviewing the titles and
abstracts, 70 were obtained for full text review
and 156 excluded. Twenty-two studies were
excluded after reviewing the full text, and two
studies were included after reviewing the refer-
ence lists of each paper. Fifty studies were eli-
gible for data extraction; six studies were
excluded due to the nature of the study popu-
lation or because they failed to report any
outcome measures of interest. Mitwalli (1991)
19
and Al-Shohaib (1999)
20 were excluded
because, although the study population was
deﬁned as dialysis patients, no further back-
ground was provided, such as the dialysis
period, and it might have included patients with
acute renal failure. Al-Mohaya (1990)
21 Yahya
(1998)
22 Raﬁ (2007)
28 and Al-Jahdali (2009)
29
were excluded because no relevant statistical
outcomes were reported (Table 1). After the
search inclusions and exclusions, 44 epidemiolo-
gical studies were eligible for the systematic
review. (Figure 1)
Characteristics of included studies
There were 40 studies conducted in Saudi Arabia
in different regions. One study was conducted in
the United Arab Emirates/Abu-Dhabi,
23 one was
conducted in Kuwait,
24 one was conducted in
Figure 1
Flow chart shows a summary of the systematic literature review
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12Table 3
Summary of reported incidence rate
Ref Author Year Location ESRD patients Sample Incidence rate Follow-up time
23 Shakuntala 1992 UAE/Abudhabi 96 NR 73.6 pmp 14 year
24 El-Reshaid 1994 Kuwait 647 NR 72 pmp 4.5 year
59 Mitwalli 1995 KSA/South-Gizan 124 654685 189.4 pmp 7 month
26 Al-Homrany 1998 KSA/South-Asir 114 NR 214.9 pmp 6 year
27 Subermanian 2001 KSA/South-Gizan NR 172446 7.44% 13 year
29 Al-Khunaizi 2003 KSA/East-Dhahran 37 250000 148 pmp 4 year
64 Al-Khunaizi 2007 KSA/East-Dhahran 12 95 13% 7 year
59 Mitwalli 1995 KSA/West-Madinah 54 828477 65.2 pmp 7 month
61 Mohamed 2004 KSA/West-Madinah 106 NR 137.5 pmp 1 year
 The mean of annual growth rate
 This estimation based on single study per 100 population
NR = not reported, PMP - per million population
Table 4
Summary of reported prevalence
Ref Author Year Location ESRD patients Sample Prevalence rate
14 Ibrahim 1992 KSA 822 5913669 138 pmp
24 El-Reshaid 1994 Kuwait NR NR 80.6 pmp
67 Al-Wakeel 2009 KSA/Centre-Riyadh 70 184 38%
Prevalence of ESRD among diabetic patients
NR = not reported
Table 5
Summary of reported mortality rate
Ref Author Year Location No. of
death
ESRD
patients
Mortality
rate
Follow-up
time
28 Al-Wakeel 2002 KSA/Centre-Riyadh 29 110 8.07% 5 year
30 Al-Muhanna 1999 KSA/East-Khobar 53 233 22.60% 15 year
29 Al-Khunaizi 2003 KSA/East-Dhahran NR 37 8% 4 year
64 Al-Khunaizi 2007 KSA/East-Dhahran 5 95 5.30% 7 year
27 Subermanian 2001 KSA/South-Gizan NR 393 9.3% 13 year
63 Mohamed 2005 KSA/West-Madinah 12 94 12.80% 6 month
34 Hussein 1994 KSA/West-Taief 46 325 14% 13 year
24 El-Reshaid 1994 Kuwait 95 647 14.70% 4.5 year
Annual death rate
NR = not reported
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25 and another one was for all the GCC.
33
There were no studies from either Oman or Qatar
meeting the inclusion criteria. The majority of
studies were either cross-sectional studies (19) or
cohort studies (19), and there were 6 case control
studies. Only 6 studies of the 44 included studies
were given a high score in methodological
quality assessment according to NOS because
most of the included studies were not reported
adequately. Although the other 38 included
studies were given a low score, they were included
in this review to avoid bias. (Table 2)
Epidemiology of ESRD in the GCC
countries
Patient’s characteristics
The mean age of participants with ESRD in
included studies ranged between 33 and 61.9
years some studies included children (aged <18
years old) but in very small proportion compared
to adults, and three studies reported neither the
age range of the study population nor mean
age.
34–36 In the United Arab Emirates, the
highest incidence rate of ESRD was reported in
Abu-Dhabi city among the 45–55 years age
group,
23 while in Kuwait the median of age
among ESRD patients was 45 years.
24 In Saudi
Arabia, incidence and prevalence of ESRD are
linkeddirectlytoincreasingage.
19,37One study con-
ducted in Asir province found that the incidence
rate of ESRD is proportional directly to increasing
age as follows: the incidence rate of the patients
who were aged between 15–44 years is 199.8
pmp, 45–64 years is 577.7 pmp, and >65 years is
716 pmp.
26 The proportion of males for all included
studies was slightly higher than females in most
included studies. Only four included studies did
not report the proportion of male to female study
participants. The study population was deﬁned as
haemodialysis patients in 24 included studies, and
other studies reported the proportion of haemodia-
lysis patients ranged between 52.1% and 97.8%. In
two studies, the study population was deﬁned as
peritoneal dialysis, while other studies reported
the proportion of peritoneal dialysis ranged
between 1.2% and 29.1%. Only ﬁve studies reported
the proportion of renal transplant ranged between
3.7% and 47.9%. (Table 2)
Incidence, prevalence, and mortality
rates of ESRD
One study conducted in a general hospital in the
United Arab Emirates in Abu-Dhabi city, reported
the annual incidence rate of ESRD at 73.6 pmp in
1992.
23 Another population-based study con-
ducted in Kuwait, reported the annual incidence
rate of ESRD as 72 pmp in 1994.
24 Six studies
were conducted in Saudi Arabia in different
regions between 1995 and 2007. It was difﬁcult
to track the trend of incidence rate between these
studies, but some of them show that the incidence
rate seems to be increasing. For example, two
studies conducted in Saudi Arabia in Al-Madinah
City, demonstrate that the incidence rate had
increased from 65.2 pmp in 1995 to 137.5 pmp in
2004;
38,39 while in another region of Saudi Arabia
in Gizan, the mean annual growth rate was
reported to be 7.44% in the period from 1987 to
2000.
27 (Table 3)
The prevalence rate of ESRD was reported in
three studies. Two studies based on national
data: one conducted in Kuwait reported the preva-
lence of ESRD as 80.6 pmp in 1994
24 and another,
which was conducted in Saudi Arabia, reported
the prevalence of ESRD as 139 pmp in 1986. This
latter estimation was based on 29 centres around
the kingdom; by geographical region the highest
prevalence was found in the central region fol-
lowed by the eastern region of Saudi Arabia.
19
The most recent study was a single centre study
estimating the prevalence of ESRD as 38%
among diabetic patients in Riyadh, the capital
city of Saudi Arabia.
14 (Table 4)
Mortality rates among ESRD patients were not
reported sufﬁciently either. Most included
studies reported the cumulative death events
ranging from 5.3% to 22.6%, which were not
useful in terms of tracking the trends in mortality
rates. Three studies were conducted in Saudi
Arabia in different regions, reporting the annual
mortality rate as follows: 9.3% in Gizan, 8% in
Riyadh and Dharan. These show that mortality
rates were not changed in the period between
2001 and 2003.
27–29 (Table 5)
Primary causes of ESRD
Meta-analysis showed that the summarized esti-
mate of diabetic nephropathy (DN) prevalence as
J R Soc Med Sh Rep 2012;3:38. DOI 10.1258/shorts.2012.011150
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14a cause of ESRD is 17.27% (95% CIs, 11.38–26.21%;
21 studies)
30,31,33,39,44–54 and there is no hetero-
geneity between the studies (I-square=zero%).
Subgroup analysis by location shows that the sum-
marized estimate of DN prevalence appears to be
higher in urban or more developed areas than
rural areas. For instance, in Saudi Arabia the
summarized estimate of DN prevalence is 31.41%;
(95% CIs, 7.39–133.59; 5 studies)
39,44,53–55 in the
western region, 29.15% (95% CIs, 9.21–92.24;
5 studies)
43,48,51,56,57 in the eastern region, and
24.98% (95% CIs, 7.01–88.98; 5 studies)
42,45–47,58
in the central region, compared to 6% (95% CIs,
2–17.8; 3 studies)
36,37,44 in the southern region,
which is considered a less developed area. These
differences between the areas are not statistically
signiﬁcant (P-value=0.32). Subgroup analysis
by period of time shows that the summarized
estimate of DN prevalence had signiﬁcantly
increased from 12.38% (95% CIs, 7.38–20.74; 9
studies)
30,31,37,44–46,48,53,58 in the period 1990-
1999 to 32.26 (95% CIs, 15.90-65.46; 11
studies)
33,36,39,42,43,47,51,54–57 in the period 2000-2010
with (P-value=0.03).
The summarizedestimate ofglomerulonephritis
prevalence as a cause of ESRD is 12.68% (95%
CIs, 8.59-18.70; 21 studies)
30,31,33,36,37,39,42–48,51,53–59
and there is no heterogeneity between the studies
(I-square=zero%). Subgroup analysis by locations
in Saudi Arabia demonstrate that the highest
estimate of glomerulonephritis (GN) prevalence
found was in the eastern region (21.67% [95% CIs,
7.74–60.66; 6 studies),
43,48,51,56,57,59 followed by the
central region (8.25% [95% CIs, 3.69–18.45; 5
studies])
42,45–47,58 western region (7.97% [95% CIs,
3.11–20.42;5studies])
39,44,53–55andsouthernregion
(7.10% [95% CIs, 2.14–23.56; 3 studies]).
36,37,44
These differences between the areas are not sta-
tistically signiﬁcant (P-value=0.39). Also, the
heterogeneity in the period of time was explored
and demonstrated that the summarized estimate
of GN prevalence had declined from 18.82%
(95% CIs, 9.65–36.69; 9 studies)
30,31,37,44–46,48,53,58
in the period between 1990–1999 to 10.36% [95%
CIs, 6.42–16.70; 11 studies]
23–34 in the period
between 2000-2010. This difference between
these two periods is not statistically signiﬁcant
(P-value=0.15).
The summarized estimate of hypertensive
nephropathy prevalence is 7.75% (95% CIs,
6.31–9.52; 17 studies)
18,21,23–27,30,32–39 and there
is no heterogeneity between the studies
(I-square = zero%). Subgroup analysis by location
shows that the highest estimate of hypertensive
nephropathy prevalence was found in Saudi
Arabia in the central region (20.08% [95% CIs,
6.12–65.89; 5 studies])
24,25,36–38 followed by
eastern region (10.56% [95% CIs, 1.80–61.77; 3
studies])
26,27,30 western region (8.13% [95% CIs,
2.95–22.42; 5 studies])
32–35,39 and southern region
(4.39% [95% CIs, 1.58–12.1; 2 studies]).
21,35 These
differences in the summarized estimates of hyper-
tensive nephropathy prevalence between areas are
not statistically signiﬁcant (P value=0.7). Also,
there is no signiﬁcant difference in the summarized
estimate of hypertensive nephropathy prevalence
in subgroup analysis by period of time, while the
summarized estimate of hypertensive nephropathy
prevalence is 7.06% (95% CIs, 3.29–15.16; 7
studies)
18,21,35–39 in the period 1990–1999 and
7.81% (95% CIs, 6.31–9.52; 9 studies)
23–27,30,32–34
in the period 2000-2010 with (P-value= 0.8).
Secondary glomerulonephritis/Vasculitis group
includes haemolytic ureamic syndrome (HUS)
and systematic Lupus erthematosus nephritis
(SLE). The prevalence of HUS as a primary
cause of ESRD reported at just 1.7% (95% CIs,
−0.16–2.74) by one study conducted in Saudi
Arabia in eastern region.
30 The summarized esti-
mate of SLE prevalence is 3.61% (95% CIs,
1.88-6.93; 10 studies)
18,24,25,28–31,36,39,40 and the
heterogeneity between the studies is high
(I-square = 89.2%).
Interstitial Nephritis/Pyelonephritis group
including: interstitial nephritis, pyelonephritis,
obstructive uropathy, and analgesic abuse. The
summarized estimate of interstitial nephritis
prevalence is 3.87% (95% CIs, 2.38–6.31; 5
studies)
23,25,30,35,40 with I-square =zero%; obstruc-
tive uropathy prevalence is 4.47% (95% CIs,
3.03–6.60; 12 studies)
19,25,26,28,29,31,32,35–38,40 with
I-square= zero%; pylonephritis prevalence is
7.45% (95% CIs, 4.81–11.56; 14
studies)
18,19,21,24,28,29,31–33,35–39 with I-square =
zero%. Analgesic abuse prevalence was reported
in two studies; one study reported the prevalence
at 1.8% (95% CIs, [−1.7–5.2]
31 and another study
reported the prevalence at 2% (95% CIs, 0.1–4).
32
Cystic/Hereditary/Congenital diseases group
includes polycystic kidney disease, medullar
cystic disease and congenital/hereditary diseases.
The summarized estimate of polycystic kidney
J R Soc Med Sh Rep 2012;3:38. DOI 10.1258/shorts.2012.011150
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15disease prevalence is 4.81% (95% [CIs, 3.05–7.60; 8
studies])
18,28–33,37 with I-square =zero%, and
medullar cystic disease prevalence is 1.43% (95%
CIs, 0.75–2.72; 3 studies)
18,32,39 with I-square =
zero%. While the summarized estimate of heredi-
tary and congenital disease prevalence is 4.43%
(95% CIs, 1.74–11.28; 8 studies)
18,25,30,31,35,36,40
with I-square= 83.5%.
The miscellaneous conditions group included
ESRD of uncertain aetiology, and otherconditions,
that are rarely reported as causes of ESRD, such
as schistosomiasis, tuberculosis, sickle cell
nephropathy and contrast nephropathy. In these
conditions for which the aetiology is unknown,
the summarized estimate is 19.59% (95% CIs,
11.23–34.17; 17 studies)
18,21,23–26,28–30,32,33,35–40
with I-square =zero, while the summarized esti-
mate for conditions that are rarely reported is
3.45 (95% CIs, 2.04–5.82; 4 studies)
28,36–38 with
I-square = zero%.
Co-morbidities associated with ESRD
Thechronicdiseasegroupincludeddiabetes,hyper-
tension, cardiovascular and vascular disease.
Meta-analysis showed that the summarized esti-
mate of diabetes prevalence is 47.85% (95% CIs,
17.47–131.05; 6 studies)
20,23,24,41–43 with I-square=
zero%, and hypertension prevalence is 77.88%
(95% CIs, 39.76–152.52; 5 studies)
20,23,24,43,44 with
I-square=zero%. The summarized estimate of car-
diovascular disease prevalence is 14.51% (95% CIs,
5.48–38.45; 6 studies)
25,28,33–36 with I-square=
38.7%. One study reported the prevalence of vascu-
lar disease as a co-morbidity condition as 11.7%
(95% CIs, 9.1–14.4).
33
Among the infectious disease group, the most
reported and prevalent infectious disease in ESRD
patients was hepatitis C virus (HCV), which is
more prevalent among haemodialysis patients
than among peritoneal dialysis patients. The sum-
marized estimate of HCV prevalence is 48.31%
(95% CIs, 29.16–80.04; 10 studies)
29,32,34,37–43 with
I-square=zero%, while hepatitis B virus infection
14.82% (95% CIs, 5.22–42.06; 3 studies)
34,40,41 with
I-square=zero%, and tuberculosis 6.80% (95%
CIs, 4.34–10.67; 5 studies)
34,44–47 with I-square=
13.3%. The prevalence of nasal carriage of staphylo-
coccus aureus, which associated with vascular
access related septicaemia, was reported as a
co-morbidity condition in HD patients in only two
studies conducted in Saudi Arabia in Al-Hafouf
City; both reported the prevalence of nasal carriage
of staphylococcus aureus as 38% (95% CIs,
7.03–205.41; 2 studies)
48,49 with I-square=zero%.
The incidence of peritonitis was reported in only
one study as 0.62% among continuous ambulatory
peritoneal dialysis patients,
50 while the prevalence
is 4.7% (95% CIs, 2.6–6.8).
Other co-morbidities and complication groups
included anaemia, bone disease, gastrointestinal
abnormalities, liver disease, depression, malnu-
trition and restless leg syndrome. Meta-analysis
showed that the summarized estimate of liver
disease prevalence is 12.74% (95% CIs, 6.71–24.2;
3 studies)
28,33,34 with I-square =zero%. The preva-
lence of anaemia was reported in two studies
in this review. One study conducted in Saudi
Arabia in Riyadh City, reported the prevalence of
anaemia as 47.5% (96% CIs, 35–60.1),
51 while
another study reported the prevalence of
anaemia for all the GCC countries to be 33.7%
(95% CIs, 29.8–37.7).
33 Bone disease was reported
in only two studies, both conducted in Saudi
Arabia, and reported the prevalence to be 28.9%
(95% CIs, 24–33.9) in Taief
31,34 and 70.2% (95%
CIs, 58.3–82.1) in Riyadh.
31 The prevalence of
depression was reported in two studies. One
study conducted in Saudi Arabia in Abha City,
reported the prevalence of depression at 59.3%
(95% CIs, 46.2–72.4);
52 while another study, which
was conducted in Bahrain reported the prevalence
of depression among men with ESRD as 48%,
which is higher than the level reported among
women 42%.
25 The prevalence of malnutrition, rest-
less leg and gastrointestinal abnormalities were
reported as 32% (95% CIs, 25.5–38.5), 50% (95%
CIs, 40.8–59.2), and 90.7% (95% CIs, 83–98.5),
respectively, in three different studies.
53–55
Causes of mortality in ESRD patients
Meta-analysis showed that the summarized esti-
mate of cardiovascular disease is 36.74 (95% CIs,
8.42–160.36; 6 studies)
23,24,28–30,34 with I-square =
zero%, while cerebrovascular disease is 3.68%
(95% CIs, 1.25–10.83; 4 studies)
24,28,30,34 with
I-square=14.8%. The summarized estimate of
sepsis is 18.97% (95% CIs, 3.14–114.68; 3
studies)
24,30,34 of the deaths in ESRD patients with
I-square=zero%. Malfunction of dialysis access
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16was reported only at one study as a cause of death
in ESRD patients at 32% (95% CIs, 17–48).
29 Pul-
monarydisease (pulmonaryinfectionandpulmon-
ary embolizm), hepatic failure, gastrointestinal
bleeding, and malignancy were all given as
causes of death in ESRD patients, and death attrib-
uted to these causes ranged from 2.1 to 11%.
29,30,34
Discussion
This review gives an overview of the demographic
distribution of ESRD patients in the countries of
the GCC. It shows that the overall proportion of
males with ESRD is slightly higher than females
in most included studies, and the most prevalent
age group is between 33 and 60 years old. This is
because the proportion of males is higher than
females in the general population in Saudi
Arabia, where most of the included studies were
conducted, while the middle age-group constitute
the majority of the population, and the elderly
people (those aged >65) constitute only 3%.
4
This clariﬁes why the proportion of elderly
patients with ESRD was small in the included
studies in this review.
The majority of ESRD patients in the GCC
countries are on haemodialysis. Renal transplan-
tation prevalence was reported in only ﬁve
studies and ranged between 3.7% and
47.9%.
23,24,27,28,34 However, the most reliable data
about renal transplantation in that area is pro-
vided by SCOT. This organization coordinates
the medical care facilities offered to patients with
ESRD and otherorganfailure; also,it is considered
the national authority in laying down the general
regulations which relate to all aspects of organ
transplantation and brain death in the kingdom.
The SCOT 2009 report shows that the number of
kidneys transplanted from living donors is more
than double the number of kidneys transplanted
from deceased donors; the number of kidneys
transplanted from living donors has been increas-
ing markedly since 1979. Approximately 40% of
ESRD patients had undergone renal transplan-
tation by 2009.
68
The incidence, prevalence and mortality rate of
ESRD in the GCC were not reported sufﬁciently in
this review. All included studies reported the
cumulative incidence rate, which does not show
changes in the trend; except one study that
reported the mean annual growth rate in Gizan
was 7.44% in the period from 1987 until 2000.
27
However, two studies in this review that were con-
ducted in Saudi Arabia in Al-Madinah city, show
that the incidence rate had increased two-fold
from 1988 to 2001.
59,61 This implies that the inci-
dence rate has been increasing gradually over
time. Furthermore, mortality rate of ESRD in this
review varied widely between studies across the
region. That may relate to differing treatment prac-
tices which contribute to the variation in out-
comes. In addition, it was difﬁcult to track the
trend of prevalence and mortality rate in this
review because of gaps in the available data.
However, SCOT data shows that the incidence
rate of haemodialysis patients is increasing
annually by 8%,
68 which may imply that the preva-
lence of ESRD is increasing without taking into
account the kidney transplant and mortality rate.
The increasing size of the ESRD population
who require RRT in the countries of the GCC
might be due to multiple factors such as the
rapid socioeconomic development in these
countries in recent decades, which has resulted
in changing lifestyle and nutrition habits.
8 This
in turn plays a role in changing the trend of the
prevalence of non-communicable disease such as
diabetes, which is globally the leading cause of
ESRD.
3 Many reports have provided evidence of
increasing prevalence of the most common
causesof ESRD in the GCC; such as obesity, hyper-
tension, and diabetes.
7,69,70 The prevalence of dia-
betes and hypertension is signiﬁcantly higher in
urban populations than rural populations and in
men rather than women. This supports the
ﬁnding in this review that the prevalence of dia-
betic nephropathy as a cause of ESRD is higher
in urban areas than rural areas, but this ﬁnding
was not statistically signiﬁcant.
Meta-analysis showed that the leading cause of
ESRD in the GCC was diabetic nephropathy 17%
followed by GN (13%) and hypertensive nephro-
pathy (8%), while the prevalence of diabetic
nephropathy had been increasing signiﬁcantly
over time. Furthermore, among all reported
co-morbid conditions in this review, hypertension
was the most prevalent chronic condition by 78%.
In addition, infectious diseases were also prevalent
co-morbid conditions, of which HCV was the most
prevalent among ESRD by 48%, especially among
haemodialysis patients; which might be due to
J R Soc Med Sh Rep 2012;3:38. DOI 10.1258/shorts.2012.011150
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17frequent attendance of patients at dialysis centres
spreading the disease through nosocomial infec-
tion
43 and the effect of nurse understafﬁng.
62
Other factors may increase the risk of HCV , such
as the length of dialysis, or the number of blood
transfusions; also diabetic patients and males are
more likely to develop HCV.
35,44,48,71
Causes of mortality and hospitalization among
ESRD patients usually result from infectious dis-
eases or complications of dialysis, or chronic
illness. Among all reported causes of death in
ESRD populations in this review, approximately
37% of deaths were related to cardiovascular
disease and 19% were related to sepsis. Two
studies reported the causes of hospitalization.
One study reported the majority cause of hospital-
ization was cardiovascular disease followed by
vascular access related problems, while ischemic
heart disease contributed to 19% of the total hospi-
talization.
28 Another study reported the main
cause of hospitalization was vascular access
related problems (34%).
63 However, one study
suggested that the optimization of arteriovenous
ﬁstula (A VF) placement might be a preventative
approach to reduce infections associated with
vascular access problems, such as staphylococcus
aureus infection, which can lead to septicaemia.
49
This suggestion is supported by the National
Kidney Foundation’s kidney disease outcomes
quality initiative (K/DOQI) clinical practice
guideline for vascular access, where A VF is the
most preferable type for permanent vascular
access for HD patients, which related to improved
quality of life and increased life expectancy in HD
patients.
72
In comparing this review with a similar publi-
cation that was undertaken for the countries of
the Middle East,
73 which the countries of the
GCC are a part, both highlighted that the inci-
dence of ESRD is increasing substantially and
that diabetes is a dominant cause of ESRD.
These ﬁndings are similar to those reported in
the USA and Europe, where diabetes was found
to be the dominant cause of ESRD.
74,75 This
review indicatesthat hypertension isthe common-
est co-morbidity in ESRD population as in the
SCOT report.
68 Furthermore, in comparing the
ﬁndings of this review with the SCOT report, we
found that the demographic distribution of age
and sex in ESRD are similar. In addition, both
show the prevalence of HCV as a co-morbidity to
be high: approximately 48% in this review and
26% in the SCOT report, which are higher than
those reported in Europe (12%) and the USA
(7%).
76
The strengths of this review are ﬁrstly, it
includes all of the epidemiological studies con-
ducted in the GCC until 2010. Secondly, this
review presents adequate and comprehensive
information based on epidemiological studies for
multiple outcomes related to ESRD. It provides
evidence of the burden of ESRD and deﬁnes the
high-risk groups; also, it records all co-morbidities
and causes of death in ESRD patients in the GCC.
This information is extremely valuable for public
health planners and administrators to allocate
healthcare resources in the countries of the GCC.
Furthermore, it gives an overview regarding the
sources and quality of the existing health data in
the GCC.
Limitations of this review include gaps in the
data which did not allow description of trends in
the prevalence and mortality rate of ESRD. The
majority of included studies in this review were
concerned with the haemodialysis population,
while there is no available data on either pre-
emptive transplantation or elderly people receiv-
ing supportive care. In addition, it is prone to a
selective bias in terms of excluding all of the
patients who received dialysis for less than three
months to exclude those patients with acute
renal failure. This might result in excluding
patients with ESRD who did not survive more
than three months. Although this review provided
an overview regarding the burden of ESRD in the
countries of the GCC, it was not able to provide
accurate and current estimates for each related
outcome, and the majority of studies were given
a low score in quality assessment because they
were not well reported. For this reason, the lack
of a national renal registry data in the countries
of the GCC is a critical issue. Sufﬁcient infor-
mation is supposed to be recorded for each
patient; such as demographic and clinical charac-
teristics, RRT, vascular access, primary causes of
ESRD, co-morbidity conditions, laboratory tests,
medications, hospitalization, death event and its
cause. Each outcome must be recorded by health-
care specialists according to standardized policy,
especially in diagnostic procedures.
16 This registry
will provide a reliable source of data for further
related epidemiological research.
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18Nevertheless, this review has several important
implications for policymakers and public health
planners. It provides evidence of the rise in the
trend and burden of ESRD in the countries of the
GCC; this helps to enable the prediction of
healthcare trends. Furthermore, it deﬁned high-
risk groups in the GCC population, who were
patients with diabetes; this emphasizes the impor-
tance of developing potential preventative strat-
egies such as screening programs to detect and
manage diabetes and chronic kidney disease
(CKD) in early stages and slow down their pro-
gression; those programs may be more cost-
effective in the future.
3,77 In fact, the quality of
care and management should be a target for
healthcare providers to improve the quality of
life and life expectancy, since hypertension and
HCV have become prevalent among ESRD
patients and may lead to increased costs of
healthcare, because patients with co-
morbidities require more hospitalization and
medications. In addition, investigating causes of
death in patients with ESRD may help to draw
the attention of healthcare professionals to speciﬁc
health issues which can lead to improved
healthcare services in that area. This may increase
the quality of life and life expectancy of ESRD
patients.
Conclusion
This isthe ﬁrst systematic review of the epidemiol-
ogy of ESRD that has been undertaken in the
countries of the GCC. There were several meth-
odological challenges that could not be overcome;
however, it was possible to construct a framework
of the epidemiology of ESRD in the countries of
the GCC. This review presents an overview of
the increasing burden of ESRD in the GCC
countries, which is similar to the rest of the
world. It also provides a list of the major causes
of ESRD in these countries and the most frequent
morbidities associated with ESRD. Accordingly,
this review suggested that the dominant cause of
ESRD in the GCC was diabetic nephropathy; and
the most frequent co-morbidities were hyperten-
sion and HCV. It highlights the emphasis on the
need of national renal registry data as a crucial
issue and preventative strategies, such as screen-
ing programs for the primary causes of ESRD
and CKD. Finally, we recommend further epide-
miological studies to describe the pattern of the
disease in the area and to improve the overall
quality of renal care management.
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